Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,977,136
  • Shares Outstanding, K 1,259,056
  • Annual Sales, $ 24,689 M
  • Annual Income, $ 123,000 K
  • 60-Month Beta 0.39
  • Price/Sales 3.32
  • Price/Cash Flow 7.81
  • Price/Book 4.47
Trade GILD with:

Options Overview

Details
  • Implied Volatility 27.12%
  • Historical Volatility 18.48%
  • IV Percentile 16%
  • IV Rank 8.46%
  • IV High 77.51% on 04/20/20
  • IV Low 22.47% on 03/23/21
  • Put/Call Vol Ratio 0.17
  • Today's Volume 19,757
  • Volume Avg (30-Day) 27,520
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 796,782
  • Open Int (30-Day) 580,873

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 1.97
  • Number of Estimates 9
  • High Estimate 2.29
  • Low Estimate 1.72
  • Prior Year 1.68
  • Growth Rate Est. (year over year) +17.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.87 +4.88%
on 03/15/21
66.84 -2.92%
on 04/01/21
+3.33 (+5.41%)
since 03/12/21
3-Month
61.39 +5.70%
on 02/26/21
69.36 -6.44%
on 02/05/21
+3.35 (+5.44%)
since 01/13/21
52-Week
56.56 +14.73%
on 12/31/20
85.79 -24.36%
on 04/17/20
-10.39 (-13.80%)
since 04/13/20

Most Recent Stories

More News
U.S. FDA Grants Accelerated Approval to Trodelvy(R) for the Treatment of Metastatic Urothelial Cancer

--- New Indication Marks Second FDA Approval for Trodelvy in 2021 -

GILD : 64.89 (+0.36%)
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study

Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.

GILD : 64.89 (+0.36%)
INCY : 80.65 (+0.98%)
MRNA : 149.71 (+7.40%)
LLY : 182.53 (+0.39%)
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

, /PRNewswire/ -- (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in...

GILD : 64.89 (+0.36%)
3 Must-Own High-Yield Pharmaceutical Stocks to Add to Your Portfolio

The pharmaceutical industry has remained a highly coveted industry since the onset of the COVID-19 pandemic. With dividend-paying biopharma stocks increasing their payouts to remain competitive amid rising...

ABBV : 108.22 (-0.03%)
GSK : 36.04 (-0.06%)
GILD : 64.89 (+0.36%)
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy

Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.

AZN : 49.19 (-0.47%)
RHHBY : 41.6900 (+0.29%)
GILD : 64.89 (+0.36%)
MRK : 76.43 (+0.28%)
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products

, /PRNewswire/ -- Conditions such as HIV, asthma, hepatitis, and severe migraines affect the quality of life of those living with these conditions. These conditions require patients to take preventive...

VPH.CN : 1.080 (-3.57%)
VPHIF : 0.8700 (-2.43%)
PFE : 37.16 (+0.51%)
ABT : 123.01 (+1.63%)
ABBV : 108.22 (-0.03%)
GILD : 64.89 (+0.36%)
FDA Approves Trodelvy(R), the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

--- Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis -

GILD : 64.89 (+0.36%)
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

JNJ : 159.48 (-1.34%)
DVAX : 9.96 (-1.09%)
GILD : 64.89 (+0.36%)
EBS : 72.76 (-4.09%)
ACAD : 20.60 (+0.83%)
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

JNJ : 159.48 (-1.34%)
DVAX : 9.96 (-1.09%)
GILD : 64.89 (+0.36%)
EBS : 72.76 (-4.09%)
ACAD : 20.60 (+0.83%)
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.

GILD : 64.89 (+0.36%)
INCY : 80.65 (+0.98%)
LLY : 182.53 (+0.39%)
ABBV : 108.22 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 66.43
2nd Resistance Point 65.82
1st Resistance Point 65.36
Last Price 64.89
1st Support Level 64.29
2nd Support Level 63.68
3rd Support Level 63.22

See More

52-Week High 85.79
Fibonacci 61.8% 74.62
Fibonacci 50% 71.18
Fibonacci 38.2% 67.73
Last Price 64.89
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar